Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heather Miller

Nurse Practitioner, Family Cape Girardeau, MO Nurse Practitioner

NPI 1396072120 CMS profile 10734012

2116 Megan Drive, Suite 102, Cape Girardeau, MO 63701

Open in the dashboard

General payments

$15,664

590 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Miller of Cape Girardeau, MO is reported in the CMS Open Payments database as having received $15,664 across 590 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,306 125
2024 General $3,258 128
2023 General $3,996 140
2022 General $2,289 82
2021 General $2,816 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Miller
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Heather Miller were reported at $3,306. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Heather Miller Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,816 $124 $35–$379 $132
2022 $2,289 $141 $44–$430 $149
2023 $3,996 $154 $49–$476 $160
2024 $3,258 $165 $51–$504 $164
2025 $3,306 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,191 134 payments
  2. Regeneron Healthcare Solutions, Inc. $1,225 38 payments
  3. UCB, Inc. $1,171 36 payments
  4. Janssen Biotech, Inc. $1,152 40 payments
  5. Novartis Pharmaceuticals Corporation $1,031 51 payments
  6. Amgen Inc. $830 32 payments
  7. E.R. Squibb & Sons, L.L.C. $818 47 payments
  8. LEO Pharma Inc. $712 29 payments
  9. Lilly USA, LLC $670 29 payments
  10. Sun Pharmaceutical Industries Inc. $655 24 payments
  11. Other $4,210 130 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,887 581 payments
  2. Education $778 9 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,278 59 payments
  2. SKYRIZI $1,206 54 payments
  3. TREMFYA $1,144 39 payments
  4. DUPIXENT $948 29 payments
  5. Bimzelx $868 20 payments
  6. Otezla $830 32 payments
  7. COSENTYX $604 31 payments
  8. SOTYKTU $594 43 payments
  9. ADBRY $582 23 payments
  10. TALTZ $523 27 payments
  11. Other $7,982 294 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

972

Median for Nurse Practitioner: 389

Drug cost

$1,071,889

Median for Nurse Practitioner: $21,885

Branded share of claims

21.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 38 $266,218
Humira(Cf) Pen Adalimumab Brand 28 $219,303
Cosentyx Unoready Pen Secukinumab Brand 13 $135,177
Cosentyx Sensoready (2 Pens) Secukinumab Brand 15 $112,019
Dupixent Pen Dupilumab Brand 26 $99,889
Dupixent Syringe Dupilumab Brand 26 $91,501
Rinvoq Upadacitinib Brand 12 $76,292
Otezla Apremilast Brand 11 $50,849
Clobetasol Propionate Generic 117 $5,085
Fluorouracil Generic 60 $4,638

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$143,857

Of which drugs: $11,767

Medicare patients

1,013

Average age 74

Services billed

3,624

645 women, 368 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 24%
Ischemic heart disease 18%
Atrial fibrillation 17%
COPD 16%
Depression 15%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 30 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $360
  • GENZYME CORPORATION $180
$541 52 —
Bimzelx
  • UCB, Inc. $464
$464 — —
RINVOQ
  • AbbVie, Inc. $315
$315 12 —
TREMFYA
  • Janssen Biotech, Inc. $213
$213 — —
SKYRIZI
  • AbbVie, Inc. $204
$204 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

590 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record